Dupixent (dupilumab) is a prescription drug that’s used to treat certain inflammatory conditions, such as atopic dermatitis (a type of eczema). Dupixent comes in a prefilled syringe or prefilled ...

Keep reading to learn about the common, mild, and serious side effects that Dupixent can cause. For a detailed overview of this drug, check out this in-depth Dupixent article. Some people may ...

Sanofi and Regeneron's Dupixent is on track to become the first targeted drug in the EU to be approved for prurigo nodularis (PN), a rare and highly debilitating skin disease. The EMA's human ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin ...

Immunology drug Dupixent is seeing very strong, steady growth in atopic dermatitis and asthma, and approvals continue to expend to new indications (nasal polyposis) and younger patients.

Immunology drug Dupixent is seeing very strong, steady growth in atopic dermatitis and asthma, and approvals continue to expend to new indications (nasal polyposis) and younger patients.

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

In Immunology, Dupixent generated sales of €3.48 billion in the quarter, up 23.8% year over year. Sales of the drug in the United States rose 19.1%, driven by strong demand in its approved ...

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical ...